Follow-up to Welcome Study C87042 [NCT00308581] Examining Certolizumab Pegol (CDP870) in Subjects With Crohn's Disease (Welcome2)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00333788 |
|
Recruitment Status :
Completed
First Posted : June 6, 2006
Results First Posted : July 12, 2011
Last Update Posted : August 7, 2018
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Crohn's Disease | Biological: Certolizumab pegol (CDP870) | Phase 3 |
Expanded Access : An investigational treatment associated with this study is available outside the clinical trial. More info ...
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 233 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Open Label Long Term Clinical Trial Evaluating Efficacy and Safety of Chronic Therapy With Certolizumab Pegol, a PEGylated Fab Fragment of Humanized Antibody to Tumor Necrosis Factor Alpha (TNF) in Patients Suffering From Crohn's Disease and Having Completed C87042 Study. |
| Study Start Date : | October 2006 |
| Actual Primary Completion Date : | April 2010 |
| Actual Study Completion Date : | April 2010 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Certolizumab pegol 400 mg
400 mg subcutaneous injection of certolizumab pegol every 2 (Q2W) or 4 (Q4W) weeks
|
Biological: Certolizumab pegol (CDP870)
400 mg subcutaneous (sc) injection of Certolizumab pegol (CDP870) every 2 (Q2W) or 4 (Q4W) weeks
Other Names:
|
- Occurrence of at Least One Study-emergent Adverse Event During the Study (Maximum 164 Weeks) [ Time Frame: Maximum 164 weeks ]
Study-emergent adverse events are defined as treatment-emergent adverse events with an onset date on or after the first study drug administration date of this study but not later than 12 weeks (84 days) after last injection.
Results are presented as the percentage of subjects with at least one treatment-emergent adverse event during this study.
- Maintenance of Response at Last Visit [Up to the Maximum Study Duration Observed in the Study (Week 154) or the Withdrawal Visit for Premature Withdrawals] Among the Subjects in Clinical Response at Baseline of This Study (Week 26 of Study C87042). [ Time Frame: Baseline (corresponding to Week 26 of study C87042 (NCT00308581) and Last Visit [Up to the maximum study duration observed in the study (Week 154) or the Withdrawal Visit for Premature Withdrawals] ]
Clinical response is defined as at least a 100 point decrease from Baseline of study C87042 (NCT00308581) in Crohn's Disease Activity Index (CDAI).
Subjects maintained their clinical response at Last Visit if they did not meet criteria for loss of response [CDAI score >150 points and a minimum increase in CDAI of 70 points versus Baseline of study C87042 (NCT00308581)] at 2 consecutive visits.
A CDAI score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
Results are presented as the percentage of subjects maintaining response at Last visit.
- Clinical Response at Last Visit [Up to the Maximum Study Duration Observed in the Study (Week 154) or the Withdrawal Visit for Premature Withdrawals] [ Time Frame: Baseline of study C87042 (NCT00308581) and Last Visit [Up to the maximum study duration observed in the study (Week 154) or the Withdrawal Visit for Premature Withdrawals] ]
Clinical response is defined as at least a 100 point decrease from Baseline of study C87042 (NCT00308581) in Crohn's Disease Activity Index (CDAI).
CDAI is used to quantify the symptoms of Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
Results are presented as the percentage of subjects achieving clinical response at Last visit.
- Remission at Last Visit [Up to the Maximum Study Duration Observed in the Study (Week 154) or the Withdrawal Visit for Premature Withdrawals] [ Time Frame: Last Visit [Up to the maximum study duration observed in the study (Week 154) or the Withdrawal Visit for Premature Withdrawals] ]
Remission is defined as a Crohn's Disease Activity Index (CDAI) score ≤ 150 points
CDAI is used to quantify the symptoms of Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
Results are presented as the percentage of subjects in remission at Last visit.
- Change From Baseline of Study C87042 (NCT00308581) in Crohn's Disease Activity Index (CDAI) at Last Visit [Up to the Maximum Study Duration Observed in the Study (Week 154) or the Withdrawal Visit for Premature Withdrawals] [ Time Frame: Baseline of study C87042 (NCT00308581) and Last Visit [Up to the maximum study duration observed in the study (Week 154) or the Withdrawal Visit for Premature Withdrawals] ]CDAI is used to quantify the symptoms of Crohn's disease. A score of 150 or below indicates remission and a score above 450 indicates extremely severe disease.
- Time to Loss of Response After Baseline of Study C87042 (NCT00308581) on Subjects Who Were in Clinical Response at Baseline of This Study [ Time Frame: Maximum 154 weeks ]
Clinical response at Baseline of this study of at least a 100 point decrease from Baseline of study C87042 in Crohn's Disease Activity Index (CDAI)
Loss of response = both a CDAI score >150 points and a minimum increase in CDAI of 70 points versus Baseline (Week 26 of study C87042) as confirmed at 2 consecutive visits. Subjects losing response will be considered as having the event on the date of the first visit where response was lost. Subjects who discontinued the study without having lost response will be censored on the date of discontinuation (i.e. date of last visit performed).
- Occurrence of at Least 1 Hospital Stay During the Treatment Period [ Time Frame: Maximum 152 weeks ]
The Treatment Period is defined from the first administration of study drug in C87046 to the last/withdrawal study drug administration visit.
Results are presented as the percentage of subjects with at least 1 hospital stay during the treatment period.
- Occurrence of at Least 1 Hospital Stay During the Follow-Up Period [ Time Frame: Maximum 12 weeks ]
Follow-up period starts the day after the last injection up to 84 days after last injection.
Results are presented as the percentage of subjects with at least 1 hospital stay during the follow-up period.
- Occurrence of at Least 1 Hospital Stay During the During the Overall Period [ Time Frame: Maximum 164 weeks ]
Overall period corresponds to both treatment and follow-up periods in C87046.
Results are presented as the percentage of subjects with at least 1 hospital stay during the overall period.
- Length of Hospital Stays During the Treatment Period [ Time Frame: Maximum 152 weeks ]The Treatment Period is defined from the first administration of study drug in C87046 to the last/withdrawal study drug administration visit.
- Length of Hospital Stays During the Follow-Up Period [ Time Frame: Maximum 12 weeks ]Follow-up period starts the day after the last injection up to 84 days after last injection.
- Length of Hospital Stays During the Overall Period [ Time Frame: Maximum 164 weeks ]Overall period corresponds to both treatment and follow-up periods in C87046.
- Occurrence of at Least 1 Emergency Room Visit During the Treatment Period [ Time Frame: Maximum 152 weeks ]
The Treatment Period is defined from the first administration of study drug in C87046 to the last/withdrawal study drug administration visit.
Results are presented as the percentage of subjects with at least 1 emergency room visit during the treatment period.
- Occurrence of at Least 1 Emergency Room Visit During the Follow-Up Period [ Time Frame: Maximum 12 weeks ]
Follow-up period starts the day after the last injection up to 84 days after last injection.
Results are presented as the percentage of subjects with at least 1 emergency room visit during the follow-up period.
- Occurrence of at Least 1 Emergency Room Visit During the Overall Period [ Time Frame: Maximum 164 weeks ]
Overall period corresponds to both treatment and follow-up periods in C87046.
Results are presented as the percentage of subjects with at least 1 emergency room visit during the overall period.
- Occurrence of at Least One Concomitant Medication Potentially Influencing Crohn's Disease During the Treatment Period [ Time Frame: Maximum 152 weeks ]
The Treatment Period is defined from the first administration of study drug in C87046 to the last/withdrawal study drug administration visit.
Medication categories are anti tumor necrosis factor (anti-TNFs), immunosuppressants, corticosteroids, 5 aminosalicylic acid (5-ASA) and antibiotics.
Results are presented as the percentage of subjects with at least 1 concomitant medication potentially influencing Crohn's disease during the treatment period.
- Occurrence of at Least One Concomitant Medication Potentially Influencing Crohn's Disease During the Follow-Up Period [ Time Frame: Maximum 12 weeks ]
Follow-up period start the day after the last injection up to 84 days after last injection.
Medication categories are anti tumor necrosis factor (anti-TNFs), immunosuppressants, corticosteroids, 5 aminosalicylic acid (5-ASA) and antibiotics.
Results are presented as the percentage of subjects with at least 1 concomitant medication potentially influencing Crohn's disease during the follow-up period.
- Occurrence of at Least One Concomitant Medication Potentially Influencing Crohn's Disease During the Overall Period [ Time Frame: Maximum 164 weeks ]
Overall period corresponds to both treatment and follow-up periods in C87046.
Medication categories are anti tumor necrosis factor (anti-TNFs), immunosuppressants, corticosteroids, 5 aminosalicylic acid (5-ASA) and antibiotics.
Results are presented as the percentage of subjects with at least 1 concomitant medication potentially influencing Crohn's disease during the overall period.
- Occurrence of at Least 1 General Concomitant Medication During the Treatment Period [ Time Frame: Maximum 152 weeks ]
The Treatment Period is defined from the first administration of study drug in C87046 to the last/withdrawal study drug administration visit.
Results are presented as the number of subjects who used at least 1 concomitant medication during the treatment period.
- Occurrence of at Least 1 General Concomitant Medication During the Follow-Up Period [ Time Frame: Maximum 12 weeks ]
Follow-up period start the day after the last injection up to 84 days after last injection.
Results are presented as the number of subjects who used at least 1 concomitant medication during the follow-up period.
- Occurrence of at Least 1 General Concomitant Medication During the Overall Period [ Time Frame: Maximum 164 weeks ]
Overall period corresponds to both treatment and follow-up periods in C87046.
Results are presented as the number of subjects who used at least 1 concomitant medication during the overall period.
- Occurrence of at Least 1 Concurrent Medical Procedure During the Treatment Period. [ Time Frame: Maximum 152 weeks ]
The Treatment Period is defined from the first administration of study drug in C87046 to the last/withdrawal study drug administration visit.
Results are presented as the number of subjects who had at least 1 concurrent medical procedure during the treatment period.
- Occurrence of at Least 1 Concurrent Medical Procedure During the Follow-Up Period [ Time Frame: Maximum 12 weeks ]
Follow-up period start the day after the last injection up to 84 days after last injection.
Results are presented as the number of subjects who had at least 1 concurrent medical procedure during the follow-up period.
- Occurrence of at Least 1 Concurrent Medical Procedure During the Overall Period [ Time Frame: Maximum 164 weeks ]
Overall period corresponds to both treatment and follow-up periods in C87046.
Results are presented as the number of subjects who had at least 1 concurrent medical procedure during the overall period.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients having completed study C87042 [NCT00308581] (previously treated with infliximab)
Exclusion Criteria:
- Subject withdraw from C87042 [NCT00308581] study
- Subject who received treatment other than certolizumab pegol and other than medications permitted in C87042 [NCT00308581] study
- Subjects from countries where certolizumab pegol is authorized in Crohn's disease treatment
- Female patients of childbearing age who are NOT practicing (in the Investigator's opinion) effective birth control. All female patients must test negative on a serum pregnancy test before study entry and negative on urine testing immediately before every certolizumab pegol administration
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00333788
Show 65 study locations
| Study Director: | UCB Clinical Trial Call Center | +1 877 822 9493 (UCB) |
| Responsible Party: | UCB Pharma |
| ClinicalTrials.gov Identifier: | NCT00333788 |
| Other Study ID Numbers: |
C87046 2006-001729-24 ( EudraCT Number ) |
| First Posted: | June 6, 2006 Key Record Dates |
| Results First Posted: | July 12, 2011 |
| Last Update Posted: | August 7, 2018 |
| Last Verified: | August 2011 |
|
Crohn's Disease Certolizumab pegol CDP870 Cimzia |
|
Crohn Disease Inflammatory Bowel Diseases Gastroenteritis Gastrointestinal Diseases Digestive System Diseases Intestinal Diseases Certolizumab Pegol |
Tumor Necrosis Factor Inhibitors Anti-Inflammatory Agents Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antirheumatic Agents |